Terms: = Ovarian cancer AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546
56 results:
1. ECPC-IDS: A benchmark endometrial cancer PET/CT image dataset for evaluation of semantic segmentation and detection of hypermetabolic regions.
Tang D; Li C; Du T; Jiang H; Ma D; Ma Z; Grzegorzek M; Jiang T; Sun H
Comput Biol Med; 2024 Mar; 171():108217. PubMed ID: 38430743
[TBL] [Abstract] [Full Text] [Related]
2. Mutation analysis of the TERT gene in ovarian cancer patients of the Turkish population by next generation sequencing method.
Capar Gorali B; Gulec Yılmaz S; Akdeniz FT; Attar R; İsbir T
Cell Mol Biol (Noisy-le-grand); 2023 Nov; 69(11):51-55. PubMed ID: 38015541
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathologic Analysis and Molecular Profiling of ovarian Steroid Cell Tumors.
Mendoza RP; Wang P; Smith HL; Fitzpatrick CA; Haridas R; Wanjari P; Briese R; Shahid A; McCluggage WG; Bennett JA
Am J Surg Pathol; 2023 Dec; 47(12):1398-1408. PubMed ID: 37796179
[TBL] [Abstract] [Full Text] [Related]
4. Chromosome instability region analysis and identification of the driver genes of the epithelial ovarian cancer cell lines A2780 and SKOV3.
Li J; Chen Z; Xiao W; Liang H; Liu Y; Hao W; Zhang Y; Wei F
J Cell Mol Med; 2023 Nov; 27(21):3259-3270. PubMed ID: 37525498
[TBL] [Abstract] [Full Text] [Related]
5. Dedifferentiated leiomyosarcoma of the uterus: a clinicopathologic and immunohistochemical analysis of 23 cases.
Chapel DB; Maccio L; Bragantini E; Zannoni GF; Quade BJ; Parra-Herran C; Nucci MR
Histopathology; 2023 May; 82(6):812-825. PubMed ID: 36704944
[TBL] [Abstract] [Full Text] [Related]
6. ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Manavella DD; McNamara B; Harold J; Bellone S; Hartwich TMP; Yang-Hartwich Y; Mutlu L; Zipponi M; Demirkiran C; Verzosa MS; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Dottino PR; Choi J; Alexandrov LB; Buza N; Hui P; Santin AD
Gynecol Oncol; 2023 Feb; 169():98-105. PubMed ID: 36525930
[TBL] [Abstract] [Full Text] [Related]
7. Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
Yoshihara M; Mogi K; Kitami K; Uno K; Iyoshi S; Tano S; Fujimoto H; Miyamoto E; Yoshikawa N; Emoto R; Matsui S; Kajiyama H
Int J Clin Oncol; 2022 Oct; 27(10):1660-1668. PubMed ID: 35906336
[TBL] [Abstract] [Full Text] [Related]
8. The Identification by Exome Sequencing of Candidate Genes in
BenAyed-Guerfali D; Kifagi C; BenKridis-Rejeb W; Ammous-Boukhris N; Ayedi W; Khanfir A; Daoud J; Mokdad-Gargouri R
Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 35893033
[TBL] [Abstract] [Full Text] [Related]
9. Refined characterization of circulating tumor DNA through biological feature integration.
Markus H; Chandrananda D; Moore E; Mouliere F; Morris J; Brenton JD; Smith CG; Rosenfeld N
Sci Rep; 2022 Feb; 12(1):1928. PubMed ID: 35121756
[TBL] [Abstract] [Full Text] [Related]
10. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic cancer InterGroup-Symptom Benefit Study.
Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky MC; Diamante K; Stockler MR; Friedlander ML;
Int J Gynecol Cancer; 2022 Jun; 32(6):761-768. PubMed ID: 35086926
[TBL] [Abstract] [Full Text] [Related]
11. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):278-287. PubMed ID: 34930617
[TBL] [Abstract] [Full Text] [Related]
12. Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
Westphalen CB; Fine AD; André F; Ganesan S; Heinemann V; Rouleau E; Turnbull C; Garcia Palacios L; Lopez JA; Sokol ES; Mateo J
Clin Cancer Res; 2022 Apr; 28(7):1412-1421. PubMed ID: 34740923
[TBL] [Abstract] [Full Text] [Related]
13. Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer.
Quan Q; Zhou S; Liu Y; Yin W; Liao Q; Ren S; Zhang F; Meng Y; Mu X
J Obstet Gynaecol Res; 2021 Apr; 47(4):1527-1535. PubMed ID: 33506580
[TBL] [Abstract] [Full Text] [Related]
14. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
15. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
[TBL] [Abstract] [Full Text] [Related]
16. The bromodomain containing protein BRD-9 orchestrates RAD51-rad54 complex formation and regulates homologous recombination-mediated repair.
Zhou Q; Huang J; Zhang C; Zhao F; Kim W; Tu X; Zhang Y; Nowsheen S; Zhu Q; Deng M; Chen Y; Qin B; Luo K; Liu B; Lou Z; Mutter RW; Yuan J
Nat Commun; 2020 May; 11(1):2639. PubMed ID: 32457312
[TBL] [Abstract] [Full Text] [Related]
17. Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study.
Simin J; Tamimi RM; Callens S; Engstrand L; Brusselaers N
Int J Cancer; 2020 Jul; 147(1):33-44. PubMed ID: 31584190
[TBL] [Abstract] [Full Text] [Related]
18. Niraparib Maintenance Therapy in Patients With Recurrent ovarian cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR
J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551
[TBL] [Abstract] [Full Text] [Related]
19. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract] [Full Text] [Related]
20. Uterine and Tubal Lavage for Earlier cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study.
Maritschnegg E; Heitz F; Pecha N; Bouda J; Trillsch F; Grimm C; Vanderstichele A; Agreiter C; Harter P; Obermayr E; Vergote I; Zeillinger R; Speiser P
Int J Gynecol Cancer; 2018 Nov; 28(9):1692-1698. PubMed ID: 30376484
[TBL] [Abstract] [Full Text] [Related]
[Next]
